<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540330</url>
  </required_header>
  <id_info>
    <org_study_id>ATOS-2015-007</org_study_id>
    <nct_id>NCT02540330</nct_id>
  </id_info>
  <brief_title>A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant</brief_title>
  <acronym>007</acronym>
  <official_title>An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atossa Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atossa Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized pharmacokinetic study of fulvestrant in women scheduled&#xD;
      for mastectomy or lumpectomy. Eligible subjects will be identified with breast cancer or&#xD;
      DCIS. The first subject of each of five groups will receive fulvestrant intramuscularly. The&#xD;
      subsequent 5 subjects of each group will receive fulvestrant by intraductal instillation. All&#xD;
      subjects will be monitored for systemic and local adverse events during the procedure, and&#xD;
      following the procedure until mastectomy or lumpectomy. Subjects that receive fulvestrant&#xD;
      will undergo serial blood draws to determine fulvestrant blood concentration levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision&#xD;
  </why_stopped>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">August 13, 2020</completion_date>
  <primary_completion_date type="Actual">August 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Two Delivery methods</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Compare the number and severity of adverse events per CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the pathological effects between the 2 routes of administration</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Determine the pathological effects, specifically changes in Ki67, ER/PgR expression between the pre-fulvestrant biopsy and the post-fulvestrant surgical specimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare fulvestrant levels by route of administration</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Compare the tissue and circulating levels of fulvestrant following a single dose administered either intramuscularly or intraductallly</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Female Breast Carcinoma</condition>
  <condition>Female Ductal Carcinoma In Situ</condition>
  <arm_group>
    <arm_group_label>Intramuscular Fulvestrant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg fulvestrant administered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intraductal Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to 500mg fulvestrant administered intraductally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <arm_group_label>Intraductal Fulvestrant</arm_group_label>
    <arm_group_label>Intramuscular Fulvestrant</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female&#xD;
&#xD;
          2. 18 years of age or older&#xD;
&#xD;
          3. Scheduled to undergo non-nipple sparing mastectomy for Invasive Breast Cancer or DCIS&#xD;
             within 1 month&#xD;
&#xD;
          4. Pathological diagnosis of Invasive Ductal Breast Cancer or Ductal Carcinoma in Situ&#xD;
             requiring mastectomy&#xD;
&#xD;
          5. Estrogen Receptor-positive pathology&#xD;
&#xD;
          6. ECOG performance scale of 0-1&#xD;
&#xD;
          7. Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/μl&#xD;
&#xD;
               -  Platelets ≥ 100,000/μl&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dl&#xD;
&#xD;
               -  Creatinine ≤ 2 times upper limit of normal&#xD;
&#xD;
               -  Bilirubin ≤ 2 times upper limit of normal&#xD;
&#xD;
               -  Transaminases (AST/SGOT and ALT/SGPT) ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          8. Able to sign informed consent&#xD;
&#xD;
          9. Willing to use effective contraception for at least 28-days post study drug&#xD;
             administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of inflammatory breast carcinoma&#xD;
&#xD;
          2. Concurrent treatment with another anti-estrogen&#xD;
&#xD;
          3. Presence of an infection including ulcerations and fungal infections in the breast to&#xD;
             be studied&#xD;
&#xD;
          4. Any condition contraindicating fulvestrant administration:&#xD;
&#xD;
               -  Subjects with bleeding diatheses, thrombocytopenia or current anticoagulant use&#xD;
&#xD;
               -  Subjects with a known hypersensitivity to fulvestrant or any of its formulation&#xD;
                  components including castor oil, alcohol, benzyl alcohol, and benzyl benzoate.&#xD;
&#xD;
               -  Several hepatic impairments, define as Child-Pugh Class C or worse&#xD;
&#xD;
          5. Prior breast surgery which interrupts communication of the ductal systems with the&#xD;
             nipple&#xD;
&#xD;
          6. Diagnosis of triple-negative or ER-negative breast cancer&#xD;
&#xD;
          7. Non-Ductal Pathology: Lobular or Colloid type presence&#xD;
&#xD;
          8. Subjects scheduled to undergo nipple sparing mastectomy&#xD;
&#xD;
          9. Prior radiation to the breast or chest wall&#xD;
&#xD;
         10. Pregnant or lactating&#xD;
&#xD;
         11. Impaired renal function&#xD;
&#xD;
         12. Impaired cardiac function or history of cardiac problems&#xD;
&#xD;
         13. Poor nutritional state (as determined by clinician)&#xD;
&#xD;
         14. Depressed bone marrow&#xD;
&#xD;
         15. Presence of serious infection&#xD;
&#xD;
         16. Presence of ascites (as determined by clinician)&#xD;
&#xD;
         17. Presence of pleural effusion&#xD;
&#xD;
         18. Allergies to Lidocaine or Novocain&#xD;
&#xD;
         19. Allergies to imaging dyes&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2015</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

